uniQure (NASDAQ:QURE) Trading Down 9.5% – What’s Next?

Shares of uniQure (NASDAQ:QURE) dropped 9.5% on Monday . The stock traded as low as $11.76 and last traded at $11.63. Approximately 633,934 shares traded hands during trading, a decline of 36% from the average daily volume of 996,189 shares. The stock had previously closed at $12.84.

Analysts Set New Price Targets

QURE has been the subject of several recent analyst reports. Raymond James raised shares of uniQure from an “outperform” rating to a “strong-buy” rating and boosted their price target for the stock from $20.00 to $52.00 in a report on Tuesday, December 10th. Mizuho upped their price target on shares of uniQure from $7.00 to $20.00 and gave the stock a “neutral” rating in a research report on Thursday, December 19th. The Goldman Sachs Group lifted their price objective on uniQure from $9.00 to $20.00 and gave the stock a “neutral” rating in a report on Thursday, December 12th. Guggenheim reissued a “buy” rating on shares of uniQure in a report on Wednesday, December 11th. Finally, Leerink Partners lifted their price target on uniQure from $26.00 to $44.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 11th. One analyst has rated the stock with a sell rating, two have issued a hold rating, six have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $40.00.

uniQure Price Performance

The company has a market cap of $559.57 million, a price-to-earnings ratio of -2.31 and a beta of 0.39. The stock has a 50 day simple moving average of $15.50 and a two-hundred day simple moving average of $9.66. The company has a debt-to-equity ratio of 0.92, a current ratio of 6.51 and a quick ratio of 6.51.

Insider Activity at uniQure

In related news, CEO Matthew C. Kapusta sold 3,418 shares of the company’s stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $7.63, for a total value of $26,079.34. Following the transaction, the chief executive officer now directly owns 597,915 shares in the company, valued at approximately $4,562,091.45. This represents a 0.57 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 4.74% of the stock is currently owned by insiders.

Hedge Funds Weigh In On uniQure

Several large investors have recently modified their holdings of QURE. RTW Investments LP purchased a new position in uniQure during the third quarter worth about $49,000. China Universal Asset Management Co. Ltd. lifted its holdings in shares of uniQure by 57.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock worth $50,000 after acquiring an additional 3,663 shares during the last quarter. Atria Investments Inc purchased a new position in shares of uniQure during the 3rd quarter worth approximately $53,000. Quarry LP acquired a new stake in uniQure in the 3rd quarter valued at approximately $58,000. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new stake in uniQure in the third quarter valued at approximately $69,000. Institutional investors and hedge funds own 78.83% of the company’s stock.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.